Evaluation of local, regional and abscopal effects of Boron Neutron Capture Therapy (BNCT) combined with immunotherapy in an ectopic colon cancer model

Trivillin, Verónica A.; Langle, Yanina; Palmieri, Mónica A.; Pozzi, Enrique J. Sánchez; Thorp, Silvia Inés; Frydryk, Debora N Benitez; Garabalino, Marcela A.; Hughes, Andrea Monti; Curotto, Paula; Colombo, Lucas L.; Cruz, Iara; Ramos, Paula; Itoiz, M. E.; Argüelles, Claudia; Eiján, Ana María; Schwint, Amanda E.

doi:10.1259/bjr.20210593

Cited by 14 publications

(15 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colorectal cancer is also ranked at leading positions in terms of prevalence and mortality, and its recurrence usually occurs within the first 2 years after removal of the primary tumor. BNCT may be an option for patients with colon and rectum tumors [58,59]. Although no clinical trials have been conducted on BNCT for colorectal cancer, a number of studies have been published on patients with colorectal liver metastases [60].…”

Section: Discussionmentioning

confidence: 99%

“…Iwakura and co-workers studied boron biodistribution in mice bearing melanotic and amelanotic melanoma after BPA was administrated intraperitoneally and found that boron concentration in melanotic melanoma was 6.72 µg/g tissue while the amelanotic one reached 5.13 µg/g tissue and these boron values were higher than in the blood, brain, skin, and liver [64]. Garabalino et al [59] studied the biodistribution of BSH injected intravenously at a dose of 50 mg 10 B/kg in hamsters with oral cancer. Boron concentration in tumors ranged from 24 to 35 ppm in 3-10 h post-administration and decreased to 9 ppm at the time point of 12 h. The maximum tumor/normal pouch boron concentration ratio was 1.8.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Laser-Synthesized Elemental Boron Nanoparticles for Efficient Boron Neutron Capture Therapy

Zavestovskaya,

Kasatova,

Kasatov

et al. 2023

IJMS

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is one of the most appealing radiotherapy modalities, whose localization can be further improved by the employment of boron-containing nanoformulations, but the fabrication of biologically friendly, water-dispersible nanoparticles (NPs) with high boron content and favorable physicochemical characteristics still presents a great challenge. Here, we explore the use of elemental boron (B) NPs (BNPs) fabricated using the methods of pulsed laser ablation in liquids as sensitizers of BNCT. Depending on the conditions of laser-ablative synthesis, the used NPs were amorphous (a-BNPs) or partially crystallized (pc-BNPs) with a mean size of 20 nm or 50 nm, respectively. Both types of BNPs were functionalized with polyethylene glycol polymer to improve colloidal stability and biocompatibility. The NPs did not initiate any toxicity effects up to concentrations of 500 µg/mL, based on the results of MTT and clonogenic assay tests. The cells with BNPs incubated at a 10B concentration of 40 µg/mL were then irradiated with a thermal neutron beam for 30 min. We found that the presence of BNPs led to a radical enhancement in cancer cell death, namely a drop in colony forming capacity of SW-620 cells down to 12.6% and 1.6% for a-BNPs and pc-BNPs, respectively, while the relevant colony-forming capacity for U87 cells dropped down to 17%. The effect of cell irradiation by neutron beam uniquely was negligible under these conditions. Finally, to estimate the dose and regimes of irradiation for future BNCT in vivo tests, we studied the biodistribution of boron under intratumoral administration of BNPs in immunodeficient SCID mice and recorded excellent retention of boron in tumors. The obtained data unambiguously evidenced the effect of a neutron therapy enhancement, which can be attributed to efficient BNP-mediated generation of α-particles.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Laser-Synthesized Elemental Boron Nanoparticles for Efficient Boron Neutron Capture Therapy

Zavestovskaya,

Kasatova,

Kasatov

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…One example is bacillus Calmette–Guérin (BCG), approved as the gold-standard treatment for non-muscle invasive bladder cancer [ 68 ]. Trivillin et al [ 69 ] proposed, for the first time, the study of the local, regional, and abscopal effects of BNCT mediated by BPA combined with bacillus Calmette–Guérin (BCG) as an immunotherapy agent. For that aim, BDIX rats were first injected subcutaneously with syngeneic colon cancer cells in the right hind flank (irradiated leg, local BNCT effect).…”

Section: Bsh Bpa Gb-10 and Boric Acid: Brief History And Optimized De...mentioning

confidence: 99%

Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies

Hughes

2023

Cancers

Self Cite

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a tumor-selective particle radiotherapy. It combines preferential boron accumulation in tumors and neutron irradiation. The recent initiation of BNCT clinical trials employing hospital-based accelerators rather than nuclear reactors as the neutron source will conceivably pave the way for new and more numerous clinical trials, leading up to much-needed randomized trials. In this context, it would be interesting to consider the implementation of new boron compounds and strategies that will significantly optimize BNCT. With this aim in mind, we analyzed, in this review, those articles published between 2020 and 2023 reporting new boron compounds and strategies that were proved therapeutically useful in in vitro and/or in vivo radiobiological studies, a critical step for translation to a clinical setting. We also explored new pathologies that could potentially be treated with BNCT and newly developed theranostic boron agents. All these radiobiological advances intend to solve those limitations and questions that arise during patient treatment in the clinical field, with BNCT and other therapies. In this sense, active communication between clinicians, radiobiologists, and all disciplines will improve BNCT for cancer patients, in a cost- and time-effective way.

show abstract

“…However, for invasive diseases like invasive bladder tumors, BCG treated alone is not an effective treatment modality. 114 Trivillin et al 115 investigated the local and regional therapeutic effects of BNCT combined with BCG as an immunotherapeutic agent both in vitro and in vivo. They found that the BCG group with neutron irradiation exhibited significantly enhanced local antitumor response compared to other control groups and demonstrated notable in vitro effects even in nonirradiated tissue.…”

Section: Combination With Immunotherapymentioning

confidence: 99%

The Dawn of a New Era: Tumor-Targeting Boron Agents for Neutron Capture Therapy

Luo,

Huang,

Chu

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

Cancer is widely recognized as one of the most devastating diseases, necessitating the development of intelligent diagnostic techniques, targeted treatments, and early prognosis evaluation to ensure effective and personalized therapy. Conventional treatments, unfortunately, suffer from limitations and an increased risk of severe complications. In light of these challenges, boron neutron capture therapy (BNCT) has emerged as a promising approach for cancer treatment with unprecedented precision to selectively eliminate tumor cells. The distinctive and promising characteristics of BNCT hold the potential to revolutionize the field of oncology. However, the clinical application and advancement of BNCT technology face significant hindrance due to the inherent flaws and limited availability of current clinical drugs, which pose substantial obstacles to the practical implementation and continued progress of BNCT. Consequently, there is an urgent need to develop efficient boron agents with higher boron content and specific tumor-targeting properties. Researchers aim to address this need by integrating tumor-targeting strategies with BNCT, with the ultimate goal of establishing BNCT as an effective, readily available, and cutting-edge treatment modality for cancer. This review delves into the recent advancements in integrating tumor-targeting strategies with BNCT, focusing on the progress made in developing boron agents specifically designed for BNCT. By exploring the current state of BNCT and emphasizing the prospects of tumor-targeting boron agents, this review provides a comprehensive overview of the advancements in BNCT and highlights its potential as a transformative treatment option for cancer.

show abstract

Evaluation of local, regional and abscopal effects of Boron Neutron Capture Therapy (BNCT) combined with immunotherapy in an ectopic colon cancer model

Cited by 14 publications

References 58 publications

Laser-Synthesized Elemental Boron Nanoparticles for Efficient Boron Neutron Capture Therapy

Laser-Synthesized Elemental Boron Nanoparticles for Efficient Boron Neutron Capture Therapy

Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies

The Dawn of a New Era: Tumor-Targeting Boron Agents for Neutron Capture Therapy

Contact Info

Product

Resources

About